glp 1 and pulmonary embolism Can GLP-1 Medications Be Considered for Weight Loss in Patients with APS? Wegovy and Blood Clots: Do

The window for market entry remains open partly due to persistent supply constraints among current manufacturers and partly because the addressable patient population continues expanding as clinical evidence mounts for GLP-1 benefits across obesity, diabetes, MASH, cardiovascular disease, and other indications

"I wouldnt recommend people take them because we dont know what the side effects are

Health literacy is needed outside health providers offices

But were still not done

The Shift from Diabetes to Weight Loss Medicine In the mid-2010s, researchers conducting diabetes trials noticed an unexpected pattern: patients were losing significant amounts of weight, often 1015% of their body mass